AURKA restricts survivin ubiquitylation and degradation in gastric cancer to promote drug resistance, and hence, the AURKA–survivin axis can be targeted to enhance the efficacy of DNA-damaging agents in treating gastric cancer (Kamran et al., 2017). This evidence concerns the gene AURKA and gastric cancer.